Table 3.
Baseline Lipoprotein Measures in Relation to Incident Diabetes, According to Randomized Treatment Arm
| Lower Tertile | Middle Tertile | Upper Tertile | Plinear trend | |
|---|---|---|---|---|
| Placebo | ||||
| LDL cholesterol (mg/dL) | ≤ 100 | 101–116 | > 116 | |
| Incidence rate per 100 p-y* | 1.40 (1.09–1.79) | 1.21 (0.94–1.57) | 0.89 (0.65–1.21) | |
| Model 1, HR (95% CI)a | 1.00 | 0.85 (0.59–1.23) | 0.57 (0.38–0.87) | 0.01 |
| cModel 2, HR (95% CI)b | 1.00 | 0.93 (0.64–1.34) | 0.54 (0.35–0.83) | 0.009 |
| HDL cholesterol (mg/dL) | ≤ 43 | 44–56 | > 56 | |
| Incidence rate per 100 p-y | 1.81 (1.47–2.25) | 1.09 (0.83–1.42) | 0.54 (0.36–0.82) | |
| Model 1, HR (95% CI) | 1.00 | 0.54 (0.37–0.78) | 0.28 (0.17–0.45) | <0.001 |
| dModel 2, HR (95% CI) | 1.00 | 0.73 (0.49–1.09) | 0.55 (0.32–0.94) | 0.03 |
| Triglycerides (mg/dL) | ≤ 96 | 97–149 | > 149 | |
| Incidence rate per 100 p-y | 0.54 (0.36–0.80) | 1.16 (0.89–1.52) | 1.79 (1.44–2.22) | |
| Model 1, HR (95% CI) | 1.00 | 2.04 (1.25–3.32) | 3.07 (1.93–4.88) | <0.001 |
| eModel 2, HR (95% CI) | 1.00 | 1.45 (0.86–2.44) | 1.87 (1.10–3.18) | 0.02 |
| Triglyceride/HDL cholesterol ratio | ≤1.78 | 1.79–3.27 | >3.27 | |
| Incidence rate per 100 p-y | 0.48 (0.30–0.71) | 1.08 (0.81–1.42) | 1.92 (1.55–2.36) | |
| Model 1, HR (95% CI) | 1.00 | 2.14 (1.27–3.58) | 3.91 (2.40–6.37) | <0.001 |
| fModel 2, HR (95% CI) | 1.00 | 1.67 (0.98–2.86) | 3.24 (1.97–5.33) | <0.001 |
| Non-HDL cholesterol (mg/dL) | ≤ 125 | 126–143 | > 143 | |
| Incidence rate per 100 p-y | 1.09 (0.82–1.45) | 0.96 (0.72–1.28) | 1.46 (1.15–1.86) | |
| Model 1, HR (95% CI) | 1.00 | 0.86 (0.57–1.29) | 1.19 (0.81–1.76) | 0.37 |
| gModel 2, HR (95% CI) | 1.00 | 0.83 (0.54–1.25) | 0.79 (0.53–1.18) | 0.25 |
| Apolipoprotein B (mg/dL) | ≤ 101 | 102–117 | > 117 | |
| Incidence rate per 100 p-y | 0.79 (0.57–1.10) | 1.35 (1.05–1.72) | 1.36 (1.05–1.75) | |
| Model 1, HR (95% CI) | 1.00 | 1.76 (1.16–2.67) | 1.76 (1.14–2.70) | 0.01 |
| Model 2, HR (95% CI) | 1.00 | 2.11 (1.28–3.46) | 1.83 (1.02–3.28) | 0.09 |
| hModel 3, HR (95% CI) | 1.00 | 1.33 (0.86–2.06) | 1.05 (0.66–1.66) | 0.99 |
| LPIR scorej (range) | ≤ 40 | 41–62 | >62 | |
| Incidence rate per 100 p-y | 0.53 (0.35–0.79) | 0.75 (0.54–1.04) | 2.21 (1.82–2.68) | |
| Model 1, HR (95% CI) | 1.00 | 1.37 (0.80–2.34) | 4.08 (2.53–6.57) | <0.001 |
| Model 2, HR (95% CI) | 1.00 | 0.73 (0.41–1.33) | 1.49 (0.80–2.78) | 0.03 |
| iModel 3, HR (95% CI) | 1.00 | 0.86 (0.48–1.54) | 2.00 (1.11–3.60) | <0.001 |
| Rosuvastatin | ||||
| LDL cholesterol (mg/dL) | ≤ 100 | 101–116 | > 116 | |
| Incidence rate per 100 p-y* | 1.92 (1.55–2.39) | 1.52 (1.20–1.93) | 1.47 (1.15–1.88) | |
| Model 1, HR (95% CI)a | 1.00 | 0.72 (0.52–1.01) | 0.73 (0.52–1.03) | 0.047 |
| cModel 2, HR (95% CI)b | 1.00 | 0.71 (0.50–1.00) | 0.66 (0.46–0.93) | 0.01 |
| HDL cholesterol (mg/dL) | ≤ 43 | 44–56 | > 56 | |
| Incidence rate per 100 p-y | 2.53 (2.10–3.05) | 1.61 (1.28–2.02) | 0.73 (0.51–1.04) | |
| Model 1, HR (95% CI) | 1.00 | 0.61 (0.44–0.83) | 0.28 (0.18–0.43) | <0.001 |
| dModel 2, HR (95% CI) | 1.00 | 0.72 (0.51–1.02) | 0.49 (0.30–0.79) | 0.003 |
| Triglycerides (mg/dL) | ≤ 96 | 97–149 | > 149 | |
| Incidence rate per 100 p-y | 0.88 (0.61–1.21) | 1.26 (0.97–1.63) | 2.78 (2.32–3.31) | |
| Model 1, HR (95% CI) | 1.00 | 1.37 (0.89–2.12) | 2.97 (2.02–4.37) | <0.001 |
| eModel 2, HR (95% CI) | 1.00 | 0.85 (0.54–1.33) | 1.43 (0.93–2.20) | 0.009 |
| Triglyceride/HDL cholesterol ratio | ≤1.78 | 1.79–3.27 | >3.27 | |
| Incidence rate per 100 p-y | 0.73 (0.50–1.02) | 1.43 (1.11–1.82) | 2.75 (2.28–3.28) | |
| Model 1, HR (95% CI) | 1.00 | 1.78 (1.14–2.77) | 3.53 (2.34–5.32) | <0.001 |
| fModel 2, HR (95% CI) | 1.00 | 1.29 (0.82–2.03) | 2.29 (1.51–3.49) | <0.001 |
| Non-HDL cholesterol (mg/dL) | ≤ 125 | 126–143 | > 143 | |
| Incidence rate per 100 p-y | 1.24 (0.95–1.61) | 1.63 (1.30–2.05) | 2.05 (1.67–2.53) | |
| Model 1, HR (95% CI) | 1.00 | 1.20 (0.84–1.73) | 1.49 (1.05–2.12) | 0.03 |
| gModel 2, HR (95% CI) | 1.00 | 0.98 (0.68–1.42) | 0.92 (0.64–1.33) | 0.65 |
| Apolipoprotein B (mg/dL) | ≤ 101 | 102–117 | > 117 | |
| Incidence rate per 100 p-y | 1.02 (0.77–1.37) | 1.77 (1.41–2.21) | 2.16 (1.76–2.64) | |
| Model 1, HR (95% CI) | 1.00 | 1.80 (1.23–2.64) | 2.22 (1.53–3.22) | <0.001 |
| Model 2, HR (95% CI) | 1.00 | 1.82 (1.17–2.83) | 2.31 (1.41–3.78) | 0.001 |
| hModel 3, HR (95% CI) | 1.00 | 1.22 (0.82–1.80) | 1.25 (0.85–1.86) | 0.28 |
| LPIR scorej (range) | ≤ 40 | 41–62 | >62 | |
| Incidence rate per 100 p-y | 0.60 (0.41–0.88) | 1.41 (1.10–1.81) | 2.90 (2.44–3.44) | |
| Model 1, HR (95% CI) | 1.00 | 2.24 (1.39–3.60) | 4.97 (3.16–7.82) | <0.001 |
| Model 2, HR (95% CI) | 1.00 | 1.22 (0.72–2.06) | 2.10 (1.20–3.66) | 0.002 |
| iModel 3, HR (95% CI) | 1.00 | 1.23 (0.73–2.07) | 2.23 (1.30–3.82) | <0.001 |
Incidence rate per 100 p-y (person-years); HR, hazard ratio; CI, confidence interval. LDL low-density lipoprotein; HDL high-density lipoprotein.
Number of incident diabetes cases among placebo- and rosuvastatin-allocated individuals were 158/6009 and 212/5909, respectively.
Model 1: Cox proportional hazards ratios were adjusted for age, sex, ethnic origin, education, exercise, family history of diabetes, and smoking
Model 2: Cox proportional hazards ratios were adjusted for Model 1 variables + systolic blood pressure, body-mass index, log transformed hsCRP, glycated hemoglobin, HDL cholesterol, LDL cholesterol, and log transformed triglycerides.
Model 2 excludes LDL cholesterol
Model 2 excludes HDL cholesterol
Model 2 excludes log transformed triglycerides
Model 2 excludes HDL cholesterol and log transformed triglycerides
Model 2 excludes LDL cholesterol and log transformed triglycerides
Model 3 excludes LDL cholesterol and log transformed triglycerides, but includes LPIR score
Model 3 excludes LDL cholesterol and log transformed triglycerides, but includes Apolipoprotein B
LPIR score ranges from 0 (most insulin sensitive) to 100 (most insulin resistant).